CliffBio
small molecule

CEFOXITIN

CEFOXITIN SODIUM

Loss of exclusivity—loss of exclusivity
CompanyFresenius Kabi →See this company's full patent-cliff portfolio

Drug detail

Brand nameCEFOXITIN
Active ingredientCEFOXITIN SODIUM
StrengthEQ 2GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Dosage formINJECTABLE
RouteINJECTION
ModalitySmall molecule
FDA approvalJuly 2000
Marketing statusDISCN

More from Fresenius Kabi

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.